Thomas Cahill - Jun 12, 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Director
Signature
/s/ Karen Brown, attorney-in-fact
Stock symbol
PRME
Transactions as of
Jun 12, 2024
Transactions value $
$0
Form type
4
Date filed
6/14/2024, 04:58 PM
Previous filing
Jun 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +45K $0.00 45K Jun 12, 2024 Common Stock 45K $7.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.